Delcath Systems (NASDAQ:DCTH) Raised to “Hold” at StockNews.com

Delcath Systems (NASDAQ:DCTH – Get Rating) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.

Separately, HC Wainwright dropped their target price on shares of Delcath Systems from $19.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, March 28th.

Delcath Systems Price Performance

Shares of Delcath Systems stock opened at $7.55 on Friday. Delcath Systems has a 1 year low of $2.34 and a 1 year high of $7.67. The firm’s 50-day moving average is $5.84 and its two-hundred day moving average is $4.52. The stock has a market cap of $80.19 million, a price-to-earnings ratio of -2.02 and a beta of 0.86.

Delcath Systems (NASDAQ:DCTH – Get Rating) last issued its earnings results on Monday, March 27th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.10). Delcath Systems had a negative return on equity of 1,396.28% and a negative net margin of 1,212.45%. The business had revenue of $0.64 million for the quarter, compared to the consensus estimate of $1.97 million. On average, equities analysts expect that Delcath Systems will post -1.58 earnings per share for the current year.

Insider Activity

In other news, CEO Gerard J. Michel purchased 19,646 shares of the stock in a transaction dated Wednesday, March 29th. The shares were acquired at an average cost of $4.84 per share, for a total transaction of $95,086.64. Following the acquisition, the chief executive officer now owns 197,235 shares of the company’s stock, valued at $954,617.40. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 16.76% of the company’s stock.

Institutional Trading of Delcath Systems

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Delcath Systems by 5.7% in the 1st quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock valued at $2,309,000 after purchasing an additional 19,605 shares during the last quarter. Cibc World Market Inc. raised its position in shares of Delcath Systems by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Delcath Systems by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 62,733 shares of the company’s stock valued at $361,000 after purchasing an additional 2,851 shares during the last quarter. BlackRock Inc. raised its position in shares of Delcath Systems by 22.3% in the 1st quarter. BlackRock Inc. now owns 16,632 shares of the company’s stock valued at $96,000 after purchasing an additional 3,032 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Delcath Systems in the 1st quarter valued at approximately $75,000. 25.66% of the stock is currently owned by institutional investors.

Delcath Systems Company Profile

(Get Rating)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.